Transient neonatal diabetes mellitus (TNDM) is estimated to occur in ~1 in 500,000 births and represents 50-60% of cases of neonatal diabetes. The pattern of inheritance of TNDM and its association with chromosome 6 uniparental disomy is consistent with the presence on chromosome 6 of an imprinted gene involved in pancreatic -cell development. Systematic screening for chromosome 6 abnormalities in nine families with 13 individuals affected by TNDM revealed paternal isodisomy of chromosome 6 in one child and paternally derived trisomy of the chromosomal region 6q in six children from three unrelated families. To delineate more accurately the region suspected of harboring the gene of interest, precise mapping of the duplicated area was performed in children exhibiting partial 6q trisomy by using microsatellite markers. The smallest region of duplication observed in our patients was flanked by markers D6S308 and D6S1010, which are separated by <1 cM. These findings confirm that TNDM may result from the overexpression of a gene located on chromosome 6q that is exclusively expressed from the paternal allele at least during some periods of life and further refine the localization of this gene. D i a b e t e s 4 9 :1 0 8-113, 2000
R e finement of the 6q Chromosomal Region Implicated in Transient Neonatal Diabetes
Hélène Cavé, Michel Polak, Séverine Drunat, Erick Denamur, and Paul Czernichow Transient neonatal diabetes mellitus (TNDM) is estimated to occur in ~1 in 500,000 births and represents 50-60% of cases of neonatal diabetes. The pattern of inheritance of TNDM and its association with chromosome 6 uniparental disomy is consistent with the presence on chromosome 6 of an imprinted gene involved in pancreatic -cell development. Systematic screening for chromosome 6 abnormalities in nine families with 13 individuals affected by TNDM revealed paternal isodisomy of chromosome 6 in one child and paternally derived trisomy of the chromosomal region 6q in six children from three unrelated families. To delineate more accurately the region suspected of harboring the gene of interest, precise mapping of the duplicated area was performed in children exhibiting partial 6q trisomy by using microsatellite markers. The smallest region of duplication observed in our patients was flanked by markers D6S308 and D6S1010, which are separated by <1 cM. These findings confirm that TNDM may result from the overexpression of a gene located on chromosome 6q that is exclusively expressed from the paternal allele at least during some periods of life and further refine the localization of this gene. T ransient neonatal diabetes mellitus (TNDM) is a developmental disease of insulin production that regresses in postnatal life. It is estimated to occur in ~1 in 500,000 births and represents 50-60% of cases of neonatal diabetes (1, 2) . Patients are usually born with intrauterine growth retardation and develop hyperglycemia, are unable to thrive, and sometimes suffer from dehydration. Insulin production is inadequate and exogenous insulin therapy is required to maintain euglycemia. Patients with TNDM do not show any evidence of anti-islet antibodies or of the t y p e 1 diabetes-associated HLA class II susceptibility haplotypes (2) . A defect in -cell maturation has been proposed to explain this condition (3). Interestingly, exocrine pancreatic insufficiency is present in some patients (4) . However, the etiology of TNDM is still unknown. Most patients recover by 1 year of age, but some patients continue to have impaired glucose tolerance, and diabetes has been shown to possibly recur in late childhood or adulthood. These recurrences are generally consistent with nonautoimmune type 1 diabetes, but their precise mechanism (insulin deficiency and/or possibly insulin resistance) remains to be determined (1, 5, 6) .
Most cases are sporadic, but in about one-third of reported cases, familial recurrences have been observed that do not follow mendelian rules of inheritance (7) . In all reported cases, transmission was of paternal origin, although the father might be unaffected by the disease (1, 8) . Paternal isodisomy of chromosome 6 has been demonstrated in several unrelated patients with TNDM (9, 10, 12) . These observations are consistent with the presence on chromosome 6 of an imprinted gene involved in the disease. Five cases of TNDM have been shown to be associated with partial duplications of the long arm of paternal chromosome 6 (11) (12) (13) (14) , but maternal duplications of the same region do not result in TNDM (12) . Moreover, interstitial deletions of the same region of the maternally inherited chromosome 6 are not associated with the disease, which makes it unlikely that TNDM is due to the absence of expression of a maternally expressed gene (15) . These findings suggest that TNDM may result from the overexpression of a gene located on chromosome 6q and exclusively expressed from the paternal allele at least during some periods of life.
All trisomies reported so far encompass the 6q23 region, while a 6q24-qter paternally derived trisomy has been reported that does not lead to TNDM (16) . Using polymorphic markers analysis and linkage analysis, Gardner et al. (17) localized the critical region between markers D6S1699 and D6S1010 (6q24.1-q24.3), which corresponds to an area of 3 -4 cM (18) .
Systematic screening for chromosome 6 abnormalities in 13 patients with TNDM enabled us to demonstrate paternal isodisomy of chromosome 6 in one child and a paternally derived partial trisomy of chromosome 6 in six children from three unrelated families. Delineation of the duplicated region permitted the chromosomal region likely to harbor the gene involved in this pathology to be further refin e d .
RESEARCH DESIGN AND METHODS

S u b j e c t s .
A total of nine families with 13 individuals affected by TNDM were studied (Table 1) . Informed consent was obtained from the patients, their parents, or both, as deemed appropriate. Twins D1 and D2, who are both affected by TNDM, were subsequently shown to be monozygous by microsatellite analysis. Main clinical features of the patients with TNDM are given in Table 1 . All patients had TNDM as defined by the following criteria: hyperglycemia, poor weight gain, and need to introduce insulin therapy within 3 months of birth (Table 1) . In all cases, insulin therapy could be stopped between the 4th and 15th months of life; therefore, all of these children had TNDM. During the follow-up, three patients (B, E, and H) had a weak insulin response to intravenous glucose tolerance tests. In addition, two patients (B and F) had episodes of glucose intolerance during acute sick-TRANSIENT NEONATALDIABETES ness some time after the neonatal period. Patient F had to be treated again with insulin from the age of 13 years, although at a very low dose. This patient had detectable C-peptide levels that were normally reactive after glucagon injection. In the families of patients B and F, numerous members have type 1 or type 2 diabetes. All but one child had intrauterine growth retardation. No dysmorphic features, except for macroglossia in one child, were observed in this cohort of children. Insulin levels, when measured at the time of diagnosis and before the start of insulin therapy, were very low or undetectable (patients A, B, and E), except in one case (patient H). In all cases, insulin secretion was clearly unadapted to glycemia. None of the children who were tested had the immune markers or the major histocompatibility complex class II haplotypes observed in type 1 diabetes. None of the patients had a defect of exocrine function that was clinically relevant or detectable by fecal fat excretion determination. Ultrasonography, when performed, did not reveal pancreatic abnormalities. Karyotypes were normal in all patients. Markers. A total of 23 simple tandem repeat (STR) markers were used: D6S105 maps at chromosome band 6p21; D6S300 maps at chromosome band 6q21; D6S261, D6S270, D6S292, D6S1699, D6S1569, D6S314, D6S1675, D6S471, D6S453, D6S310, D6S308, AFM269zg5, D6S279, D6S1704, D6S1003, D6S1010, D6S1049, D6S1703, and D6S978 maps within chromosome bands 6q22-q23; D6S311 maps at chromosome band 6q24.1; and D6S305 maps at chromosome band 6q25.
Sequences and chromosomal assignments were obtained from the Genome Database (http://www.gdb.org). STR markers were ordered according to the Genethon genetic map (18) , the Whitehead yeast artificial chromosome contigs WC6-13 and WC6-15 (http://carbon.wi.mit.edu:8000/cgi-bin/contig/phys_map), and the Sanger Center's chromosome 6 radiation hybrid map (http://www. s a n g e r. ac.uk/HGP/chr6) (Fig. 1) . Genotyping. Peripheral blood of patients and their families was collected on E D TA. DNA was extracted from leukocytes using standard methods and stored at -20°C until analysis.
A polymerase chain reaction (PCR) was carried out with a 5 fluoresceinlabeled upstream primer (Genset, Paris) using the "hot start" procedure. DNA (1 µl) was amplified in a final volume of 25 µl containing 10 pmol of 5 and 3 primers, 0.2mmol/l dNTP, 1.5mmol/lmgCl 2 , 50mmol/l KCl, 10mmol/l TRISHCl (pH 8.3), and 0.2 U Taq Polymerase (Appligene, Strasbourg, France). The PCR cycling parameters were 10 s at 94°C and 10 s at 50°C for 35 cycles carried out in an UNO-Thermoblock (Biometra, Göttingen, Germany). PCR products were analyzed using a fluorescent automated laser DNA sequencer (ABI-PRISM 310, Perkin Elmer, Norwalk, CT). Areas under the peaks were determined using the 310 Genescan (Perkin Elmer) integration software. The signal ratio for the A1 allele to the A2 allele was calculated for patients and compared with normal controls. Normal controls were DNA from normal subjects who display the same allelic pattern and/or artificial reconstitutions of normal or trisomyl patterns obtained by 1:1 and 2:1 dilutions of DNA from normal subjects exhibiting homozygous allelic patterns. In cases where trisomy was suspected, at least three PCR replicates were tested.
R E S U LT S
We studied 13 children with TNDM belonging to nine families ( Table 1) . A systematic screening for uniparental disomy of chromosome 6 was conducted by analysis of microsatellite markers D6S105, D6S300, D6S261, D6S270, D6S292, D6S310, D6S311, and D6S305 in patients and their parents. Paternal isodisomy of chromosome 6 was observed in only one patient (A). In two other patients (C and F), the allelic pattern observed for marker D6S310, which was assigned to chromosomal band 6q23.3, showed an increased gene dosage of the paternal allele, which is suggestive of a trisomy. The pattern observed for markers D6S292 (6q22.33) and D6S311 (6q24.1) was normal in these two children (Fig. 1) .
To delineate more accurately the duplicated region, additional markers spanning the 6q22-q24 region were studied in these two families. In both cases, the duplicated region included markers D6S453, D6S310, D6S308, AFM269zg5, D6S1704, and D6S1003 but excluded markers D6S471 on the centromeric side. On the telomeric side, marker D6S1010 was duplicated in child C but not in child F (Fig. 1 ). The father of child C always contributed two doses of the same allele, indicating that the duplication arose from a single chromosome, and trisomy was shown by an increased dosage of paternal alleles ( Fig. 2A) . In child F, trisomy manifested either by an increase dosage of one allele or by the presence of three alleles of different size, two of which were paternally inherited (Fig. 2B) . This suggests that, in the latter case, trisomy occurred during the first meiosis. No chromosome 6 duplication was shown in the fathers of these two chil- dren, suggesting a de novo duplication. Markers spanning and flanking the duplicated region in these two children were analyzed in the six patients for whom no chromosome 6 abnormalities were observed. Evidence of a duplication was obtained in a third family (children I, J, K, and L). Duplication was detected in the four children with TNDM and in their two fathers (Fig. 3) . The two fathers were unaffected by the disease, but subsequent oral glucose tolerance testing revealed impaired tolerance in both. It is likely that the genetic defect was transmitted via their respective mother and grandm o t h e r. Unfortunately, no genetic material was available for testing. In this family, trisomy was restricted to markers AFM269zg5, D6S1704, and D6S1003, while markers D6S308 and D6S1010 were normal ( Table 2 and Fig. 1) .
Numerous members of the paternal family of child F had diabetes. To investigate any relationship with the occurrence of a case of TNDM in this family, we analyzed the allelic pattern of chromosome 6 markers in the paternal aunt of child F, who has type 1 diabetes, and in the paternal grandmother and great-aunt, who have type 2 diabetes. Trisomy was not found in these three people, and they did not display the paternally inherited haplotypes of child F in the 6q22-24 region, which thereby excludes a direct implication of this locus in familial diabetes.
D I S C U S S I O N
This study confirms that TNDM, either familial or sporadic, is linked to the chromosomal region 6q23-24. The alterations we found are paternal uniparental disomy of chromosome 6 or 6q23-24 duplications, which are consistent with the hypothesis that TNDM is due to an increased gene dosage of a paternally expressed gene. Pooling our results with those of Gardner et al. (19) indicates that of a total of 33 unrelated children with TNDM, an abnormality of chromosome 6 was observed in 15 cases (45%) with 9 cases of uniparental disomy (27%) and 6 cases of dup(6)(q23-q24) (18%). The hypothesis that some cases of TNDM could be associated with another locus cannot be formally excluded. H o w e v e r, it is likely that at least some of the children for whom no defect was found in our and other studies harbor a genetic defect at the same gene(s), but the defect is the result of molecular mechanisms that cannot be detected using microsatellite typing and cytogenetics. 
TRANSIENT NEONATALDIABETES
Gardner et al. (17) recently localized the region of interest in TNDM between markers D6S1699 and D6S1010. Precise mapping of the duplicated area in three families enabled us to further restrict the region believed to harbor the gene of interest. The smallest region of overlap between the duplicated areas observed in our patients is contained within the region described by Gardner et al (17) . It is flanked by markers D6S308 and D6S1010, which are separated by <1 cM. PC-1 has been proposed as a candidate gene because of its overexpression in the fibroblasts of patients with type 2 diabetes (20) . Results from chromosome 6 radiation hybrid map consistently show that the PC-1 gene maps are centromeric to our region and thus cannot be the gene responsible for TNDM. Several expressed sequence tags map in the region that we have delineated. In the absence of information concerning their function, a systematic search for those that are imprinted could help to identify the gene(s) responsible for TNDM.
A familial history for diabetes has been reported in 31% of TNDM and 40% of permanent neonatal diabetes, but only few reports state the type of diabetes (8) . It is worth noting that the child in whom diabetes recurred (patient F) and the child who had glucose intolerance during acute sickness (patient B) have numerous family members with type 2 diabetes, in whom insulin resistance is an important causal phenomenon. Study of chromosome 6 markers in the members of the family of child F with diabetes suggests that the locus responsible for TNDM is independent of the one responsible for familial diabetes. In these two children, an additional genetic cause of insulin resistance could have played a role in the recurrence of diabetes.
